P95 Julius Clinical Becomes AKEURA, a Specialist CRO in Clinical Development and Real-World Evidence

The new name completes the integration of P95 and Julius Clinical, bringing clinical development and real-world evidence together in one specialist company.

P95 Julius Clinical Achieves First FDA Protocol Milestone in The Michael J. Fox Foundation’s Path to Prevention Platform Trial

The first regimen-specific protocol for The Michael J. Fox Foundation’s Path to Prevention platform trial went to the U.S. FDA just five months after the team joined as clinical operations partner.

Julius Clinical Celebrates Major GRIPonMASH Milestone

The GRIPonMASH consortium has enrolled more than 5,000 participants, passing the halfway point toward screening 10,000 people at risk of liver disease.

P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence

P95 and Julius Clinical merge into a full-service CRO of more than 500 professionals, delivering clinical development and real-world evidence across five continents.

COVIDRIVE Expands Its Scope of Studies and Becomes id.DRIVE: New European Partnership for Burden and Effectiveness Studies on Infectious Diseases

COVIDRIVE expands beyond COVID-19 to become id.DRIVE, a European public-private partnership studying infectious diseases and the real-world effectiveness of vaccines and other products.

LOGEX and P95 to Jointly Build the International Infectious Disease Observatory ARWEN ID

LOGEX and P95 agree to build ARWEN ID, an international observatory for research on infectious diseases and the impact of vaccines and other health interventions.